Differentially expressed genes in systemic sclerosis: Towards predictive medicine with new molecular tools for clinicians

Autoimmun Rev. 2023 Jun;22(6):103314. doi: 10.1016/j.autrev.2023.103314. Epub 2023 Mar 12.

Abstract

Systemic sclerosis (SSc) is a rare and chronic autoimmune disease characterized by a pathogenic triad of immune dysregulation, vasculopathy, and progressive fibrosis. Clinical tools commonly used to assess patients, including the modified Rodnan skin score, difference between limited or diffuse forms of skin involvement, presence of lung, heart or kidney involvement, or of various autoantibodies, are important prognostic factors, but still fail to reflect the large heterogeneity of the disease. SSc treatment options are diverse, ranging from conventional drugs to autologous hematopoietic stem cell transplantation, and predicting response is challenging. Genome-wide technologies, such as high throughput microarray analyses and RNA sequencing, allow accurate, unbiased, and broad assessment of alterations in expression levels of multiple genes. In recent years, many studies have shown robust changes in the gene expression profiles of SSc patients compared to healthy controls, mainly in skin tissues and peripheral blood cells. The objective analysis of molecular patterns in SSc is a powerful tool that can further classify SSc patients with similar clinical phenotypes and help predict response to therapy. In this review, we describe the journey from the first discovery of differentially expressed genes to the identification of enriched pathways and intrinsic subsets identified in SSc, using machine learning algorithms. Finally, we discuss the use of these new tools to predict the efficacy of various treatments, including stem cell transplantation. We suggest that the use of RNA gene expression-based classifications according to molecular subsets may bring us one step closer to precision medicine in Systemic Sclerosis.

Keywords: Autologous hematopoietic stem cell transplantation; Intrinsic subsets; Machine learning; RNA gene expression; Systemic sclerosis.

Publication types

  • Review

MeSH terms

  • Autoantibodies / therapeutic use
  • Autoimmune Diseases*
  • Fibrosis
  • Humans
  • Precision Medicine
  • Scleroderma, Systemic* / drug therapy
  • Scleroderma, Systemic* / therapy

Substances

  • Autoantibodies